NCT01822015已完成早期 1 期
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia
Sidney Kimmel Cancer Center at Thomas Jefferson University1 个研究点 分布在 1 个国家目标入组 55 人开始时间: 2013年3月15日最近更新:
适应症
干预措施
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 入组人数
- 55
- 试验地点
- 1
- 主要终点
- Change in measurement of mTOR activation paired with mTOR target inhibition
研究概览
简要总结
This pilot clinical trial studies sirolimus, idarubicin, and cytarabine in treating patients with newly diagnosed acute myeloid leukemia. Sirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving sirolimus together with idarubicin and cytarabine may kill more cancer cells.
详细描述
PRIMARY OBJECTIVES:
- To determine whether there is an association between baseline mammalian target of rapamycin (mTOR) activation paired with mTOR target inhibition post-treatment in leukemic blasts and clinical response in patients with newly diagnosed acute myeloid leukemia (AML) treated with sirolimus idarubicin/cytarabine.
SECONDARY OBJECTIVES:
- To estimate the response rate of sirolimus idarubicin/cytarabine in patients with newly diagnosed AML compared to historical data using idarubicin/cytarabine alone.
- To determine the ability of oral sirolimus to inhibit mTOR in leukemic blasts.
- To assess if mTOR pathway inhibition correlates with clinical response.
- To collect further information on the safety, tolerability, and efficacy of sirolimus in combination with idarubicin/cytarabine in patients with newly diagnosed AML.
- To describe the progression-free survival and overall survival (1 year, 2 year and 5 year) of patients treated with sirolimus idarubicin/cytarabine.
OUTLINE:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologic evidence of newly diagnosed acute myeloid leukemia (non-M3 AML) as documented by the presence of >20% myeloid blasts in the bone marrow
- •Subjects must be 18 years of age and <= 60
- •Subjects must have an ECOG performance status of 2 or less. (see attachment 1).
- •Subjects must have a life expectancy of at least 4 weeks.
- •Subjects must be able to consume oral medication.
- •Required initial laboratory values: Creatinine 2.0mg/dL; total or direct bilirubin 1.5mg/dL; SGPT(ALT) 3xULN (if not due to the leukemia itself); negative pregnancy test for women with child-bearing potential.
- •Patients must be able to sign consent and be willing and able to comply with scheduled visits, treatment plan and laboratory testing.
- •Subjects must have a left ventricular ejection fraction (LVEF) of >/= 45%.
排除标准
- •Subjects with APL - FAB M3 (t(15;17)(q22;q21)[PML-RAR] are not eligible
- •Subjects must not have received any chemotherapeutic agents for the AML (except Hydroxyurea). Intrathecal ARA-C and intrathecal methotrexate are permissible (as they are not systemic and only isolated to the central nervous system).
- •Subjects must not be receiving growth factors, except for erythropoietin.
- •Subjects with a "currently active" second malignancy, other than non-melanoma skin cancers are not eligible.
- •Subjects with uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure, myocardial infarction within the past 6 months or serious uncontrolled cardiac arrhythmia are not eligible.
- •Subjects taking the following are not eligible:
- •Carbamazepine (e.g., Tegretol)
- •Rifabutin (e.g., Mycobutin)
- •Rifampin (e.g., Rifadin)
- •Rifapentine (e.g., Priftin)
- •St. John's wort
- •Clarithromycin (e.g., Biaxin)
- •Cyclosporine (e.g. Neoral or Sandimmune)
- •Diltiazem (e.g., Cardizem)
- •Erythromycin (e.g., Akne-Mycin, Ery-Tab)
- •Itraconazole (e.g., Sporanox)
- •Ketoconazole (e.g., Nizoral)
- •Telithromycin (e.g., Ketek)
- •Verapamil (e.g., Calan SR, Isoptin, Verelan)
- •Voriconazole (e.g., VFEND)
- •Tacrolimus (e.g. Prograf)
- •Subjects taking fluconazole, voriconazole, itraconazole, posaconazole, and ketoconazole within 72 hours of study entry are not eligible. Reinstitution of fluconazole, voriconazole, itraconazole, posaconazole, ketoconazole and diltiazem is permissible 72 hours after the last dose of sirolimus.
- •Subjects who require HIV protease inhibitors or those with AIDS-related illness
- •Subjects with other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study are ineligible.
- •Subjects must not be pregnant or breastfeeding. Pregnancy tests must be obtained for all females of child-bearing potential. Pregnant or lactating patients are ineligible for this study due to the unknown human fetal or teratogenic toxicities of sirolimus. Males or females of reproductive age may not participate unless they have agreed to use an effective contraceptive method.
- •Subjects who have uncontrolled infection are not eligible. Patients must have any active infections under control. Fungal disease must be stable for at least 2 weeks before study entry.
- •Subjects with bacteremia must have documented negative blood cultures prior to study entry.
研究组 & 干预措施
Treatment (sirolimus, idarubicin, cytarabine)
Experimental
Patients receive sirolimus PO QD on days 1-10, idarubicin IV over 3-5 minutes on days 4-6, and cytarabine IV continuously over 24 hours on days 4-10.
干预措施: Sirolimus (Drug)
Treatment (sirolimus, idarubicin, cytarabine)
Experimental
Patients receive sirolimus PO QD on days 1-10, idarubicin IV over 3-5 minutes on days 4-6, and cytarabine IV continuously over 24 hours on days 4-10.
干预措施: Idarubicin (Drug)
Treatment (sirolimus, idarubicin, cytarabine)
Experimental
Patients receive sirolimus PO QD on days 1-10, idarubicin IV over 3-5 minutes on days 4-6, and cytarabine IV continuously over 24 hours on days 4-10.
干预措施: Cytarabine (Drug)
结局指标
主要结局
Change in measurement of mTOR activation paired with mTOR target inhibition
时间窗: Baseline to day 4
The association between mTOR response and clinical response (complete or partial response) will be evaluated using the two-sided Fisher's exact test with alpha 0.05.
次要结局
- Progression free survival(1 year, 2 years, 5 years)
- Incidence of toxicities, graded according to National Cancer Institute (NCI) Common Toxicity Criteria (CTC) 4.0 guidelines(Up to 45 days)
- Overall survival(1 year, 2 years, 5 years)
- Response defined as patients achieving a complete remission (CR), complete response in absence of total platelet recovery (CRp), or partial remission (PR)(Up to 5 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
早期 1 期
Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell TransplantationStem Cell TransplantationNCT00612274Yale University26
已完成
1 期
Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or SurgeryHepatic ComplicationNCT01888302Mayo Clinic1
终止
1 期
Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung CancerLung Non-Small Cell CarcinomaStage I Lung Cancer AJCC v8Stage IA1 Lung Cancer AJCC v8Stage IA2 Lung Cancer AJCC v8Stage IA3 Lung Cancer AJCC v8Stage IB Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8Stage IIA Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8NCT04348292Emory University3
终止
1 期
Treating Multiple Sclerosis With Sirolimus, an Immune System SuppressorMultiple Sclerosis (MS) - Relapsing-remittingNCT00095329National Institute of Allergy and Infectious Diseases (NIAID)14
进行中（未招募）
不适用
Efficacy and Safety of Sirolimus in Active Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT04582136Chinese SLE Treatment And Research Group146